RT Journal Article
T1 Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.
A1 Cruzado, Josep M
A1 Lauzurica, Ricardo
A1 Pascual, Julio
A1 Marcen, Roberto
A1 Moreso, Francesc
A1 Gutierrez-Dalmau, Alex
A1 Andrés, Amado
A1 Hernández, Domingo
A1 Torres, Armando
A1 Beneyto, Maria Isabel
A1 Melilli, Edoardo
A1 Manonelles, Anna
A1 Arias, Manuel
A1 Praga, Manuel
K1 hyperparathyroidism
K1 kidney transplantation
K1 paricalcitol
K1 vitamin D
AB Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients. This was a 6-month, investigator-initiated, multicenter, open-label, randomized clinical trial. Patients with pretransplantation iPTH between 250 and 600 pg/ml and calcium 110 pg/ml at 6 months. Secondary endpoints were bone mineral metabolism, renal function, and allograft protocol biopsies. The primary outcome occurred in 19.6% of patients in the PAR group and 36.2% of patients in the CAL group (P = 0.07). However, there was a higher percentage of patients with iPTH  Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients with iPTH 
YR 2017
FD 2017-09-28
LK https://hdl.handle.net/10668/25186
UL https://hdl.handle.net/10668/25186
LA en
DS RISalud
RD Apr 7, 2025